Acute vaginal candidosis model in the immunocompromized rat to evaluate delivery systems for antimycotics.
A rat model of vaginal candidosis, suitable for screening new antifungal compounds or novel formulations was developed and validated. Two strains of Candida albicans, different inoculation schedules, quantitative assays for fungal burden and the necessity for immunosuppression were tested. The infection was evaluated clinically and histologically by fungal counts from the vaginal discharge. The animals without immunosuppression did not sustain the infection beyond 2-3 days, however, after immunosuppression with cyclophosphamide, the infection can be maintained for about 2 weeks and is suitable for the testing of topical antifungal therapies.
Foldvari
M
M
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada. foldvari@duke.usask.ca
Radhi
J
J
Yang
G
G
He
Z
Z
Rennie
R
R
Wearley
L
L
D000208:Acute Disease; D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000503:physiopathology; D015169:Colony Count, Microbial; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005260:Female; D016867:Immunocompromised Host; D017964:Itraconazole / Q000008:administration & dosage* / Q000009:adverse effects; D051381:Rats; D014621:Vagina / Q000382:microbiology
D000935:Antifungal Agents; D017964:Itraconazole; D003520:Cyclophosphamide